Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could fasting ease the misery of pancreatitis?

NCT ID NCT04760847

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

Researchers are testing whether intermittent fasting improves quality of life for adults with acute or chronic pancreatitis. Participants follow a daily 16-hour fast or receive standard calorie guidance. The study measures pancreas-related quality of life, pain, opioid use, weight, and vitamin D levels to see if fasting helps symptoms and prevents hospital visits.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
intermittent fasting, a schedule of daily 16-hour fasts
What this could lead to
If it helps, intermittent fasting could become a low-cost, drug-free way to ease pancreas-related symptoms and reduce hospital visits for people with pancreatitis.
What could go wrong
This is a small study of 64 people, and fasting can be hard to stick with. It may not improve quality of life or pain, and dietary changes carry risks for people who are underweight or malnourished.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 64 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2027

An estimate. Start dates often move.

Expected to finish

Mar 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 year * Recurrent acute pancreatitis defined by greater than 2 episodes of pancreatitis, defined by: abdominal pain and either amylase or lipase \> 3 x the upper limit of normal, imaging suggestive of, separated by time * Anatomy of chronic pancreatitis defined by Rosemont criterion9 or on imaging (CT, MRI) * Pancreatic exocrine insufficiency defined by a pancreatic elastase \< 200 ug/g stool10 Exclusion Criteria: * Age \< 18 years * Pregnant Patients * Age \> 80 years * Patients who cannot consent for themselves * Glycogen storage disease * Insulinoma or hypoglycemic state * Active alcohol abuse * Alcohol induced acute pancreatitis * Gallstone induced acute pancreatitis * Pancreatic solid neoplasm * Patients with diabetes * Patients on beta blockers

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute recurrent pancreatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Moffitt Cancer Center

    Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.